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Abstract
Capillary electrophoresis coupled with mass spectrometry (CE-MS) has been used as a platform for discovery and validation
of urinary peptides associated with chronic kidney disease (CKD). CKD affects  10% of the population, with high associated
costs for treatments. A urinary proteome-based classifier (CKD273) has been discovered and validated in cross-sectional
and longitudinal studies to assess and predict the progression of CKD. It has been implemented in studies employing
cohorts of >1000 patients. CKD273 is commercially available as an in vitro diagnostic test for early detection of CKD and is
currently being used for patient stratification in a multicentre randomized clinical trial (PRIORITY). The validity of the CKD273
classifier has recently been evaluated applying the Oxford Evidence-Based Medicine and Southampton Oxford Retrieval Team
guidelines and a letter of support for CKD273 was issued by the US Food and Drug Administration. In this article we review
the current evidence published on CKD273 and the challenges associated with implementation. Definition of a possible surro-
gate early endpoint combined with CKD273 as a biomarker for patient stratification currently appears as the most promising
strategy to enable the development of effective drugs to be used at an early time point when intervention can still be effective.
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Introduction
Chronic diseases are one of the biggest burdens of developed
societies as a result of the increase in life expectancy. Among
these chronic diseases, chronic kidney disease (CKD) is affects
 10% of the population [1]. CKD is defined as a heterogeneous
disease generally characterized by abnormalities in kidney
structure and function lasting >3 months [2]. CKD and its final
stage, end-stage renal disease (ESRD), represent a huge eco-
nomic and personal burden. CKD has a major impact on the
quality of life and life expectancy of patients affected by this dis-
ease, especially when reaching ESRD. Based on data published
on the cost of CKD in the USA [3], it appears reasonable to estimate
that the total annual costs of CKD in Europe are >e 100 billion.
Considering the increase in life expectancy, these costs are esti-
mated to further increase by 5–10% per year.
CKD is, by definition, a chronic disease and incurable.
Intervention strategies are mostly aimed at slowing progression
and preserving kidney function as long as possible. Multiple
studies have demonstrated that early intervention is the most
effective approach in managing CKD [4].
Onset and progression of CKD is currently assessed based on
the estimated glomerular filtration rate (eGFR) calculated from
serum creatinine [5] and/or urinary albumin excretion (UAE) [6].
These biomarkers have certain shortcomings that have been
discussed in detail, including substantial variability and lack of
accuracy [7–9]. A major shortcoming, especially when considering
Received: November 2, 2016; Editorial decision: December 29, 2016
VC The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
192
Clinical Kidney Journal, 2017, vol. 10, no. 2, 192–201
doi: 10.1093/ckj/sfx002
CKJ Review
that early intervention is the most effective approach, is that
both markers are indicative of a late stage of disease. These
markers are not connected with molecular pathophysiology, but
a consequence of substantial damage to the kidney. Therefore,
there is a need for new biomarkers for detecting pre-clinical path-
ophysiological alterations at an early stage of the disease to guide
individual therapeutic interventions for prevention of disease
progression.
Proteins are responsible for structure and signalling in living
organisms and in every organ. Not surprisingly, proteins are
also the general target for drug-based intervention. Based on
these considerations, it appears only logical investigate proteo-
mic changes in the context of CKD, aiming at identifying molec-
ular changes associated with CKD onset and progression that
can be linked to molecular pathophysiology and that could
serve as more appropriate biomarkers or even as therapeutic
targets. Figure 1 illustrates this concept of how early diagnosis
and/or prognosis of diseases, based on proteomic changes
involved in pathology, improves chances for better outcomes
for patients.
Clinical proteomics
The general idea that proteins are the key molecules in disease
processes has led to development of the clinical proteomics
field. After an initial period of ‘trial and error’ [11], the field has
now matured, suggestions for appropriate study designs have
been established [12] and clinical proteomics has started deliv-
ering results that can be employed to the benefit of patients.
Mass spectrometry (MS) technologies are typically used in
clinical proteomics. Different MS technologies exist, with spe-
cific advantages and disadvantages as outlined in, for example,
Frantzi et al. [13]. The technologies enable the identification and
quantification of proteins and peptides in body fluids, tissues or
cells, hence enabling the identification of proteins that could
reflect human pathology. Especially in the context of kidney dis-
ease, one particular technology, capillary electrophoresis
coupled with mass spectrometry (CE-MS), has been optimized
and applied in multiple studies [14]. This development was also
driven by specific qualities of urine: urine can be collected non-
invasively, in large quantities, and it reflects input mostly from
the kidney ( 70% of the urine proteome is thought to originate
from the kidney) [15]. In addition, the urine proteome is quite
stable and a standard sample as well as reference values are
available [16]. The CE-MS technology consists of separation of
urinary proteins and peptides in a capillary with a high-voltage
field (CE) coupled with MS, which determines the protein
molecular mass and abundance. Reproducible sample prepara-
tion protocols, the high accuracy of MS and software develop-
ment have made the CE-MS platform highly suitable for clinical
purposes [17].
Initial studies on a smaller scale demonstrated that single bio-
markers are insufficient to display pathophysiology in a compre-
hensive way that would allow accurate assessment of disease
[18–20]. To compensate for this, and also for the high variability of
single biomarkers, the concept of multimarker approaches was
introduced. High-dimensional algorithms, such as support vector
machines (SVMs), allow combining multiple biomarkers into a
classifier, and have proven to outperform other methods for com-
bining biomarkers into a classifier [21]. However, this approach
may result in significant overfitting [22], generating classifiers
that ultimately have no value in independent samples/cohort.
This is especially an issue in small cohorts and, as such, verifying
the multimarker classifier in an independent cohort has been
Fig. 1. Early diagnosis and/or prognosis of diseases improves chances for a better outcome for the patient. The initiation of molecular processes that result in (chronic)
diseases can be detected based on molecular changes, using proteomic technologies, prior to advanced organ damage. This could allow earlier intervention where
drugs are most effective. The figure is adapted from Stepczynska et al. [10].
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highlighted as a major, mandatory, central effort in any
multimarker study [23, 24].
Following the above-mentioned considerations, CE-MS (as
shown in Figure 2) has been used in several studies in the con-
text of kidney diseases to identify urinary peptides that can be
associated with diseases and/or their progression. Urine proteo-
mics employing CE-MS can be considered as a ‘liquid biopsy’ of
the kidney and urogenital tract [25]. The kidney is a delicate and
sophisticated structure containing > 1 million multicellular fil-
tration units, the glomeruli. Glomeruli filter the blood and pro-
duce the primary urine, which is further concentrated in the
tubuli. Under normal conditions, low molecular weight proteins
and only a small fraction of proteins of middle molecular weight
pass through the glomerular filtration barriers and reach the
tubules. Because of the high efficacy of the reabsorption process
by proximal tubular epithelial cells, under physiological condi-
tions only small amounts of protein are secreted into the urine
[26]. However, under pathological conditions, initiation of
molecular changes in the protein content can be detected in
urine in a non-invasive way, thus giving rise to protein/peptide
biomarkers for CKD management. In the following paragraphs
we will discuss CE-MS application for the diagnosis and progno-
sis of CKD, ongoing studies and the current regulatory status for
clinical implementation.
The story of the CKD273 classifier
A graphic depiction of major milestones towards implementation
of CKD273 is presented in Figure 3. Based on the above-mentioned
considerations, several studies were initiated to enable detection
of CKD based on urinary proteomic changes [15, 27–30], ideally at
an early point in time when the kidney is not yet irreversibly
damaged. In one of the first larger studies involving 379 healthy
subjects and 230 patients suffering from various kidney diseases,
Good et al. [31] used CE-MS to identify urinary peptides signifi-
cantly different between patients with CKD of different aetiolo-
gies and controls with intact kidney function. The rational was to
identify biomarkers associated with CKD in general and, by com-
bining these, enable the early detection of molecular changes
that predict the development or progression of CKD. In the above
study, 273 urinary peptides were identified that significantly dif-
fered between CKD and healthy controls (all listed as supplemen
tary information, available at www.mcponline.org/content/9/11/
2424/suppl/DC1). These 273 potential biomarkers were combined
into one classifier based on urinary peptides, termed CKD273,
which was initially tested for accurate diagnosis of CKD [31]. In
the same study, CKD273 was validated in an independent test set
of 110 individuals with CKD and 34 healthy individuals, showing
a sensitivity of 85% and specificity of 100% with an area under the
curve (AUC) of 0.96 for the diagnosis of CKD. In a later study,
Molin et al. [32] investigated the performance of CKD237 in 137
urine samples (62 patients and 75 controls). This study resulted in
a similar accuracy in the diagnosis of CKD (AUC ¼ 0.96) as in the
initial study.
Major components of CKD273 are diverse collagen frag-
ments, reduced in CKD, and fragments of abundant blood-
derived proteins and/or proteins involved in inflammation (e.g.
fibrinogen, apolipoproteins, haemoglobin, alpha-1 antitrypsin
Mass SpectrometryIonization
Disease specific
Data Base
and Biomarkers 
Urine
Sample
Capillary Electrophoresis
Report
Diagnostic
Monitoring
Fig. 2. Representation of urinary CE-MS workflow. Urinary proteins are detected by CE-MS, where the mass and relative abundance of each protein is analysed. All the
detected peptides are stored in a database, which allows further evaluation of the peptides to be used for diagnostic purposes.
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etc.), increased in CKD. Peptides in CKD273 can be linked to the
kidney, and to CKD pathophysiology, as also indicated in
Figure 4. The parental proteins (giving rise to the peptides) are
present in the kidney, some (e.g. uromodulin or type I collagen)
in high quantities [33]. As such, it is reasonable to assume that
the peptide biomarkers were generated in the kidney, reflecting
CKD-associated molecular changes, and the peptide changes
observed in CKD urine can be associated with biological proc-
esses intimately linked to CKD. The reduction of collagen frag-
ments indicates attenuation of collagen degradation, which
results in increased deposits of collagen in the kidney tissue, in
fibrosis. In fact, fibrosis is a key element of CKD, and fibrosis is
tightly associated with CKD progression [34]. An increase in
alpha-1 antitrypsin degradation, and consequently a reduction
of alpha-1 antitrypsin protein levels, may support inflammation
and could also promote fibrosis: alpha-1 antitrypsin was found
to attenuate renal fibrosis [35].
Assessment and prediction of CKD using
the CKD273 classifier
A graphic depiction of the studies published to date using
CKD273 is presented in Figure 5 and a short description of each
of these studies is listed in Table 1. To establish an added value
in patient management, CKD273 was assessed in several stud-
ies. The classifier demonstrated applicability in a longitudinal
study including samples from type 1 and 2 diabetic patients
observed over an average of 10 years. In this study, CKD273 out-
performed UAE in predicting diabetic kidney disease (AUC of
CKD273 0.93 versus AUC of UAE 0.67) [37]. Following these posi-
tive results, CKD273 was further evaluated for its ability to pre-
dict change from normoalbuminuria to microalbuminuria
and from microalbuminuria to macroalbuminuria using sam-
ples from a prospective study over 3 years. Investigating
88 samples from patients with type 2 diabetes mellitus, superior
performance of CKD273 in predicting class changes in albumi-
nuria over UAE was demonstrated [38]. Next, the CKD273 classi-
fier was tested in 53 patients at various CKD stages,
demonstrating value in the prediction of CKD progression to
ESRD [39]. The prediction of CKD progression was also con-
firmed in a large population-based cohort of 797 individuals
over an average of 4.8 years [45]. In a large multicentric cohort
of 1990 individuals, which included 522 subjects where 3-year
follow-up data were available, the prognostic value of CKD273
was assessed. The findings verified CKD273 to be a better pre-
dictor of CKD progression than UAE [41]. In an additional very
recent study, the superiority of CKD273 over albuminuria in pre-
dicting CKD progression was demonstrated in 737 samples from
the Diabetic Retinopathy Candesartan Trials (DIRECT) 2 cohort
[44]. Furthermore, the prediction of CKD progression was inves-
tigated in detail in a large cohort of 2672 individuals at various
CKD stages, aimed at specifying the value of CKD273 in compar-
ison with the state of the art to predict eGFR loss at different
baseline glomerular filtration rate (GFR) strata [43]. The results
demonstrated that CKD273 performed much better than albu-
minuria in predicting loss of GFR at an early CKD stage (eGFR
>70 mL/min/1.73 m2), but provided no advantage in patients
with advanced-stage disease (eGFe <50 mL/min/1.73 m2), where
albuminuria appears to have better performance. The applica-
tion of CKD273 to predict risk of death or development of vascu-
lar complications on top of kidney diseases or to assess the
aetiology of kidney diseases [46] should be further investigated.
Treatment and ongoing research exploring
the CKD273 classifier
Beyond prognostic value, CKD273 also depicts the impact of
treatment, showing its potential in assessing therapeutic inter-
ventions, as has also been previously shown for other urinary
peptides [47]. CKD273 scores were significantly altered after
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Fig. 3. Major milestones on the path towards implementation of CKD273. Shown are the main milestones and developments from the initial discovery until the issuing
of the FDA Letter of Support.
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treatment with irbesartan (an antihypertensive and antiprotei-
nuric drug): specifically, a change towards values of healthy
individuals was detectable after 2 years of treatment with irbe-
sartan [48]. Of note, an immediate impact of irbesartan treat-
ment on CKD273 was not detectable, indicating that the drug
does not act on molecular targets directly involved in CKD. In a
very recent study, the value of CKD273 in predicting response to
spironolactone was investigated [49]. The results of the study
demonstrated that a higher baseline score in CKD273 was sig-
nificantly associated with a response to spironolactone (as
assessed via albuminuria reduction).
The above results have also initiated the implementation of
CKD273 in a large multicentric randomized clinical trial stratify-
ing patients based on risk of CKD progression. In the PRIORITY
(Proteomic prediction and Renin angiotensin aldosterone sys-
tem Inhibition prevention Of early diabetic nephRopathy in
TYpe 2 diabetic patients with normoalbuminuria) trial, CKD273
is employed to select a population at high risk of progression
towards CKD to assess if spironolactone prevents early diabetic
nephropathy (using microalbuminuria as the endpoint) in dia-
betic patients without pathological albuminuria [50].
Preliminary results of this PRIORITY trial further confirmed the
validity of CKD273 as a clinical assay for patient risk stratifica-
tion in interventional trials [40, 44].
Current regulatory status of the CKD273 classifier
The performance of CKD273 as a biomarker for clinical studies
was further investigated in a recent systematic review by
Critselis and Lambers Heerspink [36]. The Oxford Evidence-
Based Medicine (EBM) and Southampton Oxford Retrieval Team
(SORT) guidelines for the prognostic value of tests were applied
to CKD273. The authors identified several studies that con-
firmed the validity and value of the classifier for predicting CKD
progression (Table 2). The CKD273 classifier obtained a high
score at level Ib to be employed in randomized controlled trials
according to the Oxford EBM.
The US Food and Drug Administration (FDA) has recently
issued a letter of support for CKD273 (http://www.fda.gov/down
loads/Drugs/DevelopmentApprovalProcess/UCM508790.pdf).
The letter aims to encourage the visibility of CKD273 and to sup-
port further evaluation and studies to establish its clinical utility
in ‘prognostic enrichment, drug development and study design
Inhibition of matrix metalloproteases (e.g. MMP2 and MMP9) 
Increased collagen accumulation
Reduced degradation of collagens
Excessive accumulation of ECM 
Renal fibrosis and 
inflammation
u-Collagens↓
Reducted renal function / proteinuria
Apoptosis/chronic inflammation (ROS, AGE) 
u-Plasma 
proteins ↑
u-A1AT ↑
Decrease of GFR
Fig. 4. Biological processes generally accepted to be involved in CKD onset and
progression. The processes are indicated in the boxes. Outside, peptides found
significantly changes in CKD are indicated, at the respective step in the disease
development. [36].
CKD stages
GFR level
(mL/min/1.73m2)
Andersen et al. 2010 48
Argiles et al. 2013 39 
Gu et al. 2014 45
Siwy et al. 2014 40 Siwy et al. 2014 40
Zürbig et al. 2012 37
Roscioni et al. 2013 38
Schanstra et al. 2015 41
Pontillo et al. 2016 43
<1515-2930-5960-89>90
Molin et al. 2012 32 Molin et al. 2012 32
Lindhardt et al. 2016 44
1. Early-stage 3. Moderate 
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2. Mild 
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renal disease
Pontillo et al. 2015 52
Fig. 5. Representation of the studies evaluating the performance of the CKD273-classifier in the diagnosis and prognosis of CKD according to disease stage. The bars
show the CKD stages in which the classifier was used. The Figure is adapted from Critselis and Lambers Heerspink [36].
196 | C. Pontillo and H. Mischak
T
ab
le
1.
Li
st
o
f
st
u
d
ie
s
p
u
bl
is
h
ed
th
at
su
p
p
o
rt
th
e
be
n
efi
t
o
f
C
K
D
27
3
St
u
d
y
ba
ck
gr
o
u
n
d
St
u
d
y
in
fo
rm
at
io
n
N
u
m
be
r
o
f
sa
m
p
le
s
St
u
d
y
ty
p
e
Pe
rf
o
rm
an
ce
(C
K
D
27
3)
C
o
m
p
ar
at
o
r
Pe
rf
o
rm
an
ce
(c
o
m
p
ar
at
o
r)
R
ef
er
en
ce
D
ia
gn
o
si
s
o
f
D
N
in
T
2D
p
at
ie
n
ts
D
ia
gn
o
si
s:
m
ac
ro
al
bu
m
in
u
ri
a
13
7
C
ro
ss
-s
ec
ti
o
n
al
Se
n
s.
95
%
Sp
ec
.8
9%
A
U
C
0.
96
—
—
M
o
li
n
et
al
.[
32
]
Pr
ed
ic
ti
o
n
o
f
D
N
in
T
2D
p
at
ie
n
ts
N
o
rm
al
bu
m
in
u
ri
c
p
at
ie
n
ts
tr
an
si
ti
o
n
to
m
ac
ro
al
bu
m
in
u
ri
a
31
6
(3
5
p
at
ie
n
ts
)
Lo
n
gi
tu
d
in
al
5-
ye
ar
fo
ll
o
w
-u
p
:A
U
C
0.
93
N
o
rm
al
bu
m
in
u
ri
c
sa
m
p
le
s:
A
U
C
0.
92
U
A
E
5-
ye
ar
fo
ll
o
w
-u
p
:
A
U
C
0.
86
N
o
rm
al
bu
m
in
u
ri
c
sa
m
p
le
s:
A
U
C
0.
67
Z
u¨
rb
ig
et
al
.[
37
]
Pr
ed
ic
ti
o
n
o
f
tr
an
si
ti
o
n
to
h
ig
h
er
al
bu
m
in
u
ri
a
st
ag
es
T
ra
n
si
ti
o
n
fr
o
m
n
o
rm
o
-
to
m
ic
ro
al
bu
m
in
u
ri
a,
tr
an
si
ti
o
n
fr
o
m
m
ic
ro
-
to
m
ac
ro
al
bu
m
in
u
ri
a
88
Lo
n
gi
tu
d
in
al
A
U
C
0.
94
O
R
1.
35
eG
FR
þ
U
A
E
A
U
C
0.
91
R
o
sc
io
n
ie
t
al
.[
38
]
A
ss
o
ci
at
io
n
w
it
h
re
n
al
h
ar
d
en
d
p
o
in
ts
C
o
rr
el
at
io
n
w
it
h
U
A
E
an
d
eG
FR
as
so
ci
at
io
n
w
it
h
d
ea
th
o
r
d
ia
ly
si
s
af
te
r
3.
6
ye
ar
s
53
Lo
n
gi
tu
d
in
al
—
U
A
E
—
A
rg
il
es
et
al
.[
39
]
M
u
lt
ic
en
tr
ic
d
ia
gn
o
si
s
o
f
D
N
in
T
2D
p
at
ie
n
ts
D
ia
gn
o
si
s:
m
ac
ro
al
bu
m
in
u
ri
a
16
7
C
ro
ss
-s
ec
ti
o
n
al
A
U
C
0.
95
–1
.0
0
—
—
Si
w
y
et
al
.[
40
]
D
ia
gn
o
si
s
an
d
p
re
d
ic
ti
o
n
o
f
C
K
D
p
ro
gr
es
si
o
n
Pr
o
gn
o
si
s:
eG
FR
d
ec
li
n
e
>
5%
p
er
ye
ar
19
90
52
2
C
ro
ss
-s
ec
ti
o
n
al
Lo
n
gi
tu
d
in
al
A
U
C
0.
82
1
eG
FR
þ
U
A
E
A
U
C
0.
75
8
Sc
h
an
st
ra
et
al
.[
41
]
D
ia
gn
o
si
s
an
d
ri
sk
o
f
p
ro
gr
es
si
o
n
to
C
K
D
Pr
o
gn
o
si
s:
eG
FR
d
ec
li
n
e
>
4
m
L/
m
in
/
1.
73
m
2
/y
ea
r
35
Lo
n
gi
tu
d
in
al
A
U
C
0.
98
Se
n
s.
95
%
Sp
ec
.1
00
%
U
A
E
(d
ip
st
ic
k)
A
U
C
0.
85
O
vr
eh
u
s
et
al
.[
42
]
Pr
ed
ic
ti
o
n
o
f
d
ec
li
n
e
in
gl
o
m
er
u
la
r
fi
lt
ra
ti
o
n
eG
FR
st
ra
ta
o
f
10
m
L/
m
in
/1
.7
3
m
2
Pr
o
gn
o
si
s:
eG
FR
d
ec
li
n
e
>
5
m
L/
m
in
/
1.
73
m
2
/y
ea
r
26
27
Lo
n
gi
tu
d
in
al
eG
FR
>
80
:A
U
C
0.
65
2
eG
FR
70
–7
9:
A
U
C
0.
70
0
U
A
E
eG
FR
>
80
:A
U
C
0.
58
0
eG
FR
70
-7
9:
A
U
C
0.
57
7
Po
n
ti
ll
o
et
al
.[
43
]
Po
st
h
o
c
an
al
ys
is
o
f
th
e
D
IR
EC
T
-P
ro
te
ct
2
tr
ia
l
N
o
rm
al
bu
m
in
u
ri
c
p
at
ie
n
ts
R
C
T
w
it
h
ca
n
d
es
ar
ta
n
en
d
p
o
in
t:
m
ic
ro
al
bu
m
in
u
ri
a
73
7
Lo
n
gi
tu
d
in
al
H
R
2.
65
A
U
C
0.
79
U
A
E
eG
FR
H
R
2.
03
H
R
1.
40
Li
n
d
h
ar
d
t
et
al
.[
44
]
Pr
ed
ic
ti
o
n
o
f
C
K
D
st
ag
e
3
Lo
n
gi
tu
d
in
al
st
u
d
y,
p
re
d
ic
ti
o
n
o
f
C
K
D
st
ag
e
3
20
87
Lo
n
gi
tu
d
in
al
H
R
1.
23
U
A
E
eG
FR
H
R
1.
06
H
R
0.
71
Po
n
ti
ll
o
et
al
.,
su
b-
m
it
te
d
fo
r
p
u
bl
i-
ca
ti
o
n
[5
2]
D
N
,;
H
R
,h
az
ar
d
ra
ti
o
;T
2D
,;
Se
n
s.
,s
en
si
ti
vi
ty
;S
p
ec
.,
sp
ec
ifi
ci
ty
.
Urinary CKD273 classifier for kidney disease | 197
considerations’. In particular, the FDA affirmed that the pro-
posed use of the classifier for prognosis of early diabetic kidney
disease is consistent with the FDA’s guidance ‘Enrichment
Strategies for Clinical Trials to Support Approval of Human
Drugs and Biological Products’. This is an important achieve-
ment: to date, the FDA has only issued 12 letters of support in
total; the one for CKD273 is the only one in the context of CKD.
To further confirm the prognostic utility of the classifier, sur-
rogates and earlier endpoints for CKD are being investigated. In
2014, the European Medicines Agency (EMA) [51] suggested that
primary efficacy endpoints for compound testing should be pre-
vention or delay of renal function decline, defined as either time
to occurrence or incidence rate of CKD stage 3, with or without
prevention of proteinuria/albuminuria. Therefore, CKD273 was
employed in a study to predict early CKD progression, as sug-
gested by EMA, comparing its performance with clinical parame-
ters using CE-MS data from 2087 subjects with baseline eGFR60
mL/min/1.73 m2. The results clearly demonstrate that CKD273
enables prediction of progression to CKD stage 3 with signifi-
cantly superior performance than any other variables generally
employed (age, gender, body mass index, blood pressure, eGFR
and UAE) (unpublished data, submitted as abstract) [52].
Based on the above-mentioned data and evaluation results,
CKD273 is now available as an in vitro diagnostic device in
Germany for the early detection of CKD in diabetic patients. The
procedure has been standardized, the urine sample is shipped
overnight to the analytical laboratory, and the results are
reported back to the sender within 5 days. However, as outlined
below, currently this service is only available for privately
insured patients.
Future perspectives
While CKD273 is available for early detection of CKD for individ-
ual patients in Europe, implementation for the publicly insured
population is still being debated. Discussions are ongoing with
the G-BA, the German authority regulating reimbursement in
the health care system. It is very concerning that these discus-
sions were initiated in 2011, yet no definitive conclusion has
been reached.
A major argument against implementation of the classifier
towards clinical use is the lack of studies demonstrating a sig-
nificant positive effect on the accepted hard endpoint (ESRD or
death). While such a demand may appear sensible at first sight,
it is at the same time unrealistic, as it would require a study
over a period of 15–20 years (from early, subclinical disease to
endpoint), likely including enormous numbers of patients (sev-
eral hundred thousand), and prohibiting intervention with any
new drug (that was not available at the start of the study). It is
obvious that such a study cannot be performed and that it
would not receive ethics approval. Demands for such studies
effectively prohibit bringing benefits to patients and hinder the
development of therapeutic drugs. The demand for a trial on a
hard endpoint rests on the argument of the absence of a proven
benefit of early intervention and the hypothesis that molecular
changes may be different in early CKD and are not targeted by
the currently used drugs. However, such arguments contradict
current literature and knowledge.
As recently demonstrated in a comprehensive analysis by
Schievink et al. [4], intervention at the earliest time point shows
the greatest benefit. This is also evident when evaluating CKD
on a mechanistic level. As depicted in Figure 6, from the initially
healthy status (a), CKD generally starts with reversible damage
in some glomeruli (b); at this point in time, these damages may
be reversed. Without treatment, additional glomeruli will be
damaged (c), a few beyond the point where effective treatment
may be possible. At the same time, pressure on the remaining
intact glomeruli increases and damage of individual glomeruli
is further accelerated (d), with subsequent detectable impact on
total kidney functional parameters (albuminuria and/or eGFR).
The molecular mechanisms addressable by therapeutic inter-
vention (indicated by the yellow glomeruli in Figure 6) are the
same at this later stage than at the beginning. However, the
irreversible damage has occurred to multiple glomeruli (indi-
cated by red and black in Figure 6), and glomeruli lost cannot be
replaced. While progression from (d) to (e) and (f) cannot be pre-
vented, as a result of too high a burden on the few remaining
glomeruli, it could likely be prevented with intervention at (b) or
(c), at a stage where molecular changes displayed by CKD273 are
evident but functional parameters are not yet affected.
Prevention of implementation of potential benefits for
patient management is even more puzzling when considering
that all studies to date have shown a positive result, and espe-
cially also in the light of the societal challenges associated with
CKD (see above) and the evidence for a health economic profit
in several assessments [33, 53]. It is unclear why, in the light of
all the evidence, implementation of novel beneficial approaches
meet such substantial resistance (possibly to not endanger busi-
ness models resting on the status quo). Ultimately, the current
situation indicates that precision medicine, as exemplified by
the application of CKD273, may only be available for the weal-
thy, but not for the general society.
A further future perspective is application in the develop-
ment of ‘humanized’ animal models [54]. It has become evident
that animal models do not well-reflect human disease on a
molecular level [55]. Using CKD273, the animal model most
closely resembling human disease (based on similarity in
molecular changes) could be identified, thereby generating a
‘humanized model’ that will enable substantial improvement in
Table 2. Oxford EBM [50] and SORT [40] evidence level score regarding the validity of the CKD273 classifier in CKD prediction
Methodology
Samples collection
at a common point
Sufficient
follow-up
time
Blind
outcome
criteria
Adjustment
for prognostic
factors
EBM
score
SORT
score
Argiles et al. [39] Prospective cohort No Yes Yes No Ib 1
Gu et al. [45] Prospective cohort No Yes Yes Yes * 2
Roscioni et al. [38] Prospective cohort Yes Yes Yes Yes Ib 4
Schanstra et al. [41] Prospective cohort Yes Yes Yes Yes Ib 4
*Not calculated (follow-up time insufficient). The table was adapted from Critselis and Lambers [36].
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preclinical testing, increasing the chances of success in human
subjects (Figure 7) [54].
CKD273 has demonstrated a significant improvement over
the current state of the art in detecting CKD at a very early point
in time, when intervention is more likely to be successful and
prevention of CKD progression appears feasible. A further area
of application is supporting the development of therapeutic
drugs that interfere with CKD progression, as CKD273 predicts
the risk of CKD progression and can be used as an inclusion cri-
terion in clinical trials. However, as outlined above, the develop-
ment of such treatments and design of interventional clinical
trials are often prevented by the demand to address the long-
term renal endpoint of the disease, ESRD. In this regards, efforts
towards defining earlier endpoints and to early predict progres-
sion of CKD, where drug intervention would be effective, would
be beneficial. The definition of an early surrogate endpoint (e.g.
CKD stage 3) combined with CKD273 as a biomarker for patient
stratification would give a substantial boost to the development
of new drugs to prevent CKD.
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Fig. 7. Humanized model concept. Improving the translatability of animal models of disease with the development of a multimolecular humanized readout. The analy-
sis of multiple urinary proteomic changes in the animal model allows identifying, similar (ortholog) changes in human disease and animal models, leading to a
humanized readout, which will more efficiently translate the effects of new drugs in preclinical models to the clinic.
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Fig. 6. Schematic concept of CKD onset and progression. The kidney contains 1 million filtration units (glomeruli). From the initially healthy status (a), some glomeruli
experience pathological molecular changes (yellow) reversibly compromising their function. Without treatment, additional glomeruli will be damaged (c), a few also
beyond the point where effective treatment may be possible (red). As pressure on the remaining intact glomeruli increases, damage of individual glomeruli is further
accelerated (d), with now detectable impact on kidney functional parameters (albuminuria and/or eGFR), and the first glomeruli are lost (black). The molecular mecha-
nisms are identical at this later stage to the beginning, but irreversible damage has occurred to multiple glomeruli, which cannot be repaired. Progression from (d) to (e)
(established CKD, most glomeruli damaged, many beyond repair or completely lost) and then to (f) (ESRD, very few glomeruli still functional) cannot be prevented
because of the too high burden on the few remaining glomeruli. Prevention would have been possible with intervention at (b) or (c), stages where molecular changes
displayed by CKD273 are evident but functional parameters are not yet affected.
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